Centessa Pharmaceuticals (Centessa Pharmaceuticals) Change In Inventory : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals Change In Inventory?

Centessa Pharmaceuticals's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Centessa Pharmaceuticals's inventory stayed the same from Dec. 2023 to Mar. 2024 .

Centessa Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Centessa Pharmaceuticals's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Centessa Pharmaceuticals's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Centessa Pharmaceuticals Change In Inventory Historical Data

The historical data trend for Centessa Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals Change In Inventory Chart

Centessa Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Centessa Pharmaceuticals Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial										-	-	-	-	-

Centessa Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Centessa Pharmaceuticals (NAS:CNTA) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Centessa Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Centessa Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Centessa Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Centessa Pharmaceuticals Change In Inventory Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Centessa Pharmaceuticals (Centessa Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (NAS:CNTA) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

260:Germany

Address

1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT

Website

https://www.centessa.com

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Executives

Harris Rotman	officer: SVP Regulatory Affairs	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Antoine Yver	officer: Chief Medical Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Tia L Bush	officer: Chief Quality Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Karen M. Anderson	officer: Chief People Officer	C/O MIMECAST LTD., 191 SPRING STREET, LEXINGTON MA 02421
David J Grainger	officer: Chief Innovation Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Gregory M Weinhoff	officer: Chief Financial Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Thomas Templeman	officer: Chief Technology Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
David M Chao	officer: Chief Administrative Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Iqbal J Hussain	officer: General Counsel	C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH
Mathias Hukkelhoven	director	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Saurabh Saha	director, officer: Chief Executive Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Javad Shahidi	officer: Chief Medical Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Medicxi Ventures Management (jersey) Ltd	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Rubertis Francesco De	director	C/O MEDICXI, COURS DE RIVE 10, GENEVA V8 CH-1204
Aaron Kantoff	director	C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH